Kaveri Pohlman
Stock Analyst at BTIG
(0.42)
# 2,858
Out of 4,479 analysts
20
Total ratings
17.65%
Success rate
-26.28%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Maintains: Buy | $24 → $9 | $4.10 | +119.51% | 3 | May 24, 2024 | |
| CGEM Cullinan Oncology | Maintains: Buy | $20 → $30 | $16.31 | +83.94% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $18.26 | +108.11% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $2.98 | +67.79% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $39.30 | +57.76% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $2.94 | +172.11% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $22.15 | +21.90% | 1 | Dec 19, 2023 | |
| GMAB Genmab | Maintains: Buy | $44 → $46 | $24.90 | +84.74% | 2 | Oct 13, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $14.65 | +377.82% | 1 | Aug 23, 2023 | |
| STTK Shattuck Labs | Initiates: Buy | $12 | $3.64 | +229.67% | 1 | Aug 31, 2022 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $16 → $8 | $1.32 | +506.06% | 2 | Jul 7, 2022 | |
| NEXI NexImmune | Initiates: Buy | $125 | $2.48 | +4,940.32% | 1 | Jun 1, 2022 | |
| ONCT Oncternal Therapeutics | Initiates: Buy | $100 | $7.05 | +1,318.44% | 1 | Feb 24, 2022 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $1,540 → $616 | $0.88 | +69,900.00% | 1 | Feb 9, 2022 |
MacroGenics
May 24, 2024
Maintains: Buy
Price Target: $24 → $9
Current: $4.10
Upside: +119.51%
Cullinan Oncology
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $16.31
Upside: +83.94%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $18.26
Upside: +108.11%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $2.98
Upside: +67.79%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $39.30
Upside: +57.76%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $2.94
Upside: +172.11%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $22.15
Upside: +21.90%
Genmab
Oct 13, 2023
Maintains: Buy
Price Target: $44 → $46
Current: $24.90
Upside: +84.74%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $14.65
Upside: +377.82%
Shattuck Labs
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $3.64
Upside: +229.67%
CytomX Therapeutics
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $1.32
Upside: +506.06%
NexImmune
Jun 1, 2022
Initiates: Buy
Price Target: $125
Current: $2.48
Upside: +4,940.32%
Oncternal Therapeutics
Feb 24, 2022
Initiates: Buy
Price Target: $100
Current: $7.05
Upside: +1,318.44%
Sonnet BioTherapeutics Holdings
Feb 9, 2022
Maintains: Buy
Price Target: $1,540 → $616
Current: $0.88
Upside: +69,900.00%